SIGA Technologies, Inc. is a small biotech company committed to developing novel 
products for the prevention and treatment of serious viral diseases, with an 
emphasis on products to combat outbreaks that could result from bioterrorism. 
With government support, SIGA has developed the necessary infrastructure to 
successfully advance new antiviral drugs from the discovery stage through to 
licensing. Currently, there is a need to develop safe and effective inhibitors 
for poxvirus-induced diseases such as smallpox caused by variola, which is a 
potential biological warfare agent. Likewise emerging zoonotic infections due to 
cowpox virus and monkeypox virus require the development of effective 
countermeasures. Tecovirimat, also known as ST-246, has shown efficacy in all 
small animal and nonhuman primate prophylaxis and therapeutic efficacy models of 
poxvirus-induced disease tested to date. Phase I clinical trials and new drug 
application-enabling toxicology studies have been completed with tecovirimat. A 
phase II clinical study is being run and SIGA has initiated commercial scale-up 
manufacturing and preparation for the pivotal safety and efficacy studies. SIGA 
is committed to getting approval for tecovirimat and supplying it to the 
Strategic National Stockpile, the Department of Defense and global health 
authorities.